NCCN guidelines are evidence-informed, consensus-driven, and influential in US payer policies, with a focus on multidisciplinary representation and global adaptations. ESMO guidelines reduce care ...

Lung cancer in never-smokers exhibits distinct biological characteristics, often leading to late-stage diagnoses due to lack of screening. Targeted therapies, guided by molecular testing, offer ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

More Americans are living with cancer as death rates continue to decline, thanks to improved detection methods and better ...

“Lung cancer, though common and serious, still has many misconceptions,” says Ian Bostock, MD, a thoracic surgeon at Miami Cancer Institute in Florida. “Clearing these myths helps patients and ...

CHICAGO - Lung cancer is responsible for approximately 1 in 4 cancer deaths in the United States, making it the deadliest ...

A 60-year-old’s routine health screening revealed stage 1 lung cancer – a reminder that the disease can strike anyone, and ...